. Janet

SAS/DC:dm 02/02/05 6235-59221-01 341891

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Morishita et al.

Application No. 09/869,475

Filed: October 10, 2001 Confirmation No. 4309

For: GENE THERAPY FOR DIABETIC

ISCHEMIC DISEASE

Examiner: Brian A. Whiteman

Art Unit: 1635

Attorney Reference No. 6235-59221-01

COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent for Applicant(s

Date Mailed February 3, 2005

INFORMATION DISCLOSURE STATEMENT **PURSUANT TO 37 C.F.R. § 1.97(c)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several Englishlanguage documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this IDS.

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6235-59221-01
Application Number	09/869,475
Filing Date	October 10, 2001
First Named Inventor	Morishita
Art Unit	1635
Examiner Name	Brian A. Whiteman

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Numb	er Public	Publication Date		Name of Applicant or Patentee	
L							
			FOREIGN PATE	NT DOCUME	NTS		
Examiner's Initials*	Cite No.	Country	Number	Publicatio	n Date	Name of Applicant or Patentee	

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 98/19712 A1	05/14/1998	St. Elizabeth's Medical Center
					of Boston, Inc.
		WIPO	WO 98/51798 A1	11/19/1998	Imperial Cancer Research
					Technology Limited
		WIPO	WO 00/62798 A2	10/26/2000	St. Elizabeth's Medical Center
					of Boston, Inc.
		WIPO	WO 00/62798 A3	10/26/2000	St. Elizabeth's Medical Center
					of Boston, Inc.
Examiner's	Cite No.	OTHER DOCUMENTS			

Initials*	(optional)	OTHER DOCUMENTS
	i	

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.